

AmCad BioMed Corp.

code: 4188

2022 Institutional Investor Conference

Established: 2008

Year of Listing: 2015

Capital: USD18.9M

Chairperson: Yili Lee

CEO

Yili Lee


AmCad BioMed Corp.

- ▶ **Founded** : Dec. 2008
- ▶ **Business** : Product development, Manufacturing and Sales for Innovative Medical Device
- ▶ **Products** :  
- ▶ **Capital** : TWD 530M
- ▶ **President** : Yili Lee
- ▶ **Subsidiary** : Broadsound Corporation

*CAD = Computer Aided Detection

Amcad
Pioneering Ultrasound AI

Major Milestones



Roadmap of Medical Innovation Development



AmCad BioMed

execution:

- ▶ CE MDR certificate.
- ▶ Continue to promote domestic hospitals and health diagnosis channels.
- ▶ Execute **post-market clinical research** and **paper publication** with well-known teaching hospitals at home and abroad, and expand product application.
- ▶ To accumulate product popularity by exhibiting , Internet publicity.

Business Model of Innovative Medical Device



CDMO / Licensing

Use our expertise in developing product according to our strategic partners' needs/specifications.



Distribution

Leasing

Revenue
Sharing

Outright
Sales

Subscription

Exclusive or regional rights, single & multi-product deals.



Collaborative Marketing

Collaborate with enterprise imaging solutions providers to expand market access.



安克生醫股份有限公司
AmCad BioMed Corporation


Product Lines




- Automated ultrasound scanning and detection of pharyngeal airway
- Risk evaluation of obstructive sleep apnea (OSA)
- FDA 510(k), CE certified



- FDA 510(k), CE certified
- Imaging of the backscattered signals for assessment of tissue variation



- FDA 510(k), CE, TFDA, CFDA certified
- Assessment of malignancy potential for thyroid nodule sonographic features
- Risk analysis of malignancy for thyroid nodule



- Breast Ultrasound AI Live CAD



- Cytology microscopic image processing
- Visualization and quantification of clinical cytology features




- Point of care ultrasound device
- Real time AI imaging


AmCAD UT[®] Features



- FDA 510(k), CE, TFDA, CFDA certified
- Automated nodule identification and segmentation
- Patented technologies to visualize and quantify sonographic features
- Recommendation based on TI-RADS and global guidelines
- Automated report generation




Visualization of Thyroid
Ultrasound Features



Automated report generation

AmCAD UO[®] Features



Detection system for Obstructive Sleep Apnea

- FDA 510(k), CE, TFDA certified
- Patented Laser Guided Positioning
- Algorithmic Detection and Analysis
- Automated Upper Airway Scanning on Awake Patients
- Effective detection of OSA severity



2022 Operating Updates



美吾華·懷特·安克生技集團
Maywufa Biopharma Group

2022 Milestones – AmCAD UT[®]



- ▶ Implement AmCAD UT[®] and start business in **Min Sheng** and **Yang Ming Chiao Tung Hospital** in 2022Q1 .
- ▶ Completed **Cathay General Hospital** IRB verification to increase the efficiency of clinical process .(combined with **AmCAD UT[®]** and **AmCAD CA[®]**)
- ▶ **AmCAD UT[®]** CFDA certification extended to 2027.
- ▶ **AmCAD UT[®]** has been used by **300 doctors in 131 hospitals** worldwide and **28 papers** have been published.

Cathay General Hospital – AmCAD UT[®] Thyroid AI Diagnosis

Amcad continues to promote thyroid AI diagnosis.
If it is successfully implemented, it can greatly reduce the waiting time of patients.



國泰綜合醫院
Cathay General Hospital

國泰綜合醫院
10630 台北市仁愛路二段280號
Cathay General Hospital
No. 280, Sec. 4, Ren'ai Rd.,
Daan Dist., Taipei City, Taiwan
Tel: 02-27082121

國泰醫療財團法人國泰綜合醫院人體試驗審查委員會

Institutional Review Board of the Cathay General Hospital

同意計畫修正證明書

本會編號：CGH-P110058

計畫名稱：電腦輔助之甲狀腺超音波影像與細胞學分析(人工智慧模型)流程整合性評估之研究

計畫主持人：王文弘

協同主持人：劉之怡

試驗機構：耳鼻喉科

修正內容：變更收案人數

計畫書版本編號：Version 4.0, 30-May-2022

計畫書摘要版本編號：Version 4.0, 30-May-2022

試驗期限：110 年 09 月 25 日至 111 年 08 月 01 日

期中報告繳交頻率：每半年

1. 期中報告：本臨床試驗每屆滿半年本會將進行追蹤審查，請於有效期限前二個月，繳交期中報告以利本會審查，如尚未通過期中報告與有效期間延遲審查者，試驗不得繼續執行。
2. 追蹤報告：應依本委員會審查通過時之決議，定期繳交報告至本委員會審查。
3. 結案報告：試驗完成後，應將執行結果依結案報告表送至本委員會審查。試驗結束後三個月仍未繳交者，不得申請新試驗之審查。
4. 嚴重不良事件(SAE)報告：試驗主持人應根據衛生福利部「藥品優良臨床試驗原則」和「嚴重藥品不良反應通報辦法」規定，辦理相關事宜。
5. 本會有暫停/終止本研究計畫及撤銷本執行許可書之權責。

國泰醫療財團法人國泰綜合醫院人體試驗審查委員會

主任委員 汪志雄



中華民國 一 一 一 年 六 月 一 日



安克生醫股份有限公司
AmCad BioMed Corporation

AmCAD UT[®] Pricing approval in China

► Obtained UT license at 2022/1/28.

中华人民共和国医疗器械注册证

注册证编号：国械注许20172212261


注册人名称	安克生医股份有限公司 安克生醫股份有限公司
注册人住所	桃園市楊梅區青山里獅二路12號2樓 桃園市楊梅區青山里獅二路12號2樓
生产地址	桃園市楊梅區青山里獅二路12號2樓 桃園市楊梅區青山里獅二路12號2樓
代理人名称	美吾发化妆品（上海）有限公司
代理人住所	上海市徐汇区虹桥路777号902室
产品名称	甲状腺超声图像处理软件 安克甲状腺
型号、规格	型号：AmCAD-UT Detection 发布版本：Version2.2（c）
结构及组成	物理组成：包括光盘、USB金钥、使用手册；逻辑组成：包括用户界面、DICOM影像读取、感兴趣区域（ROI）选取、超声图像特征处理、报告生成5个模块。
适用范围	用于选取超声灰阶图像中的感兴趣区域（ROI），对ROI区域进行图像处理。
附件	产品技术要求
其他内容	/
备注	原注册证编号：国械注许20172702261

审批部门：国家药品监督管理局



批准日期：二〇二二年一月七日
生效日期：二〇二二年七月七日
有效期至：二〇二七年七月六日


► Obtained 7 provinces Pricing approval in China.



A decorative horizontal bar consisting of seven blue squares of varying shades, with the second square from the left being a lighter blue and slightly larger than the others.

Google My Maps

Taiwan Institution Adoption Map- AmCad UT




2022 Milestones – AmCAD UO®



- ▶ Study results of trial collaborated with **Stanford Sleep Medicine Center** published at 2022 World Sleep.
- ▶ Established European Exhibition Center in Germany.
- ▶ American Academy of Orthodontics publishes application of braces.
- ▶ Obtained order from Thailand distributor.
- ▶ **AmCAD UO®** is used in **NTUH Health Management Center** in August 2021, and will Start business in Harvard Clinic soon.

Clinical Study with Stanford-2022 World Sleep Publication

The 16th World Sleep 2022 (World Sleep 2022) debuted in Italy from 3/11 to 3/16. Anker Biomedical and Stanford Sleep Medicine Center jointly published clinical results, proving that different races can achieve "non-invasive" Compared with traditional "invasive" endoscopy and sleep center detection, the sonic smart imaging medical materials show a high degree of consistency, which is expected to assist physicians in the diagnosis and treatment of apnea.




International Study Publication



Stanford Sleep Clinics Otolaryngology – Drug Sleep Endoscopy DISE Study



Cleveland Clinics Dental School Dental – Oral appliance braces treatment



Frankfurt American Sleep Clinics Sleep Center –Medical Triage

American Association of Orthodontists 2022

Miami Beach

May 21~24, 2022, 12,000 + attendees



American
Association of
Orthodontists®



Product Development

Future outlook—AmCAD UO[®]

Multiple cross-domain companion applications


- ▶ Global sleep apnea devices market size was valued at USD 3.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028. (from [Grand view Research](#))
- ▶ In addition to being used for rapid detection, AmCAD UO[®] is also actively expanding its use in Companion Diagnosis. Through the diagnosis of AmCAD UO[®], it also provides physicians with future treatment directions for apnea, including positive pressure respirator, braces, surgical resection, laser ablation, nerve stimulation, etc.
- ▶ US, Germany, and Taiwan have carried out relevant verification studies.



Mandibular advancement device (MAD)
Advance mandible gradually daily
Increase the oropharyngeal airway opening



Tongue retractor
Hold the tongue forward
Lower dental arch
Mandible



UPPP



MMA





Amcad UB AI Live Breast Ultrasound Features :

- ▶ **Seamlessly integrate AI into the clinical process of hand-held ultrasonography to maximize the advantages of ultrasonography :**
 - Simultaneous detection and diagnosis during scanning.
 - Simultaneous display of B-mode & CAD sonic images.
 - Automatically select image slices, circle the most likely lesion features and the largest area of possible lesions.
 - Automatically generate reports after scanning

- ▶ **Use real-time detection and intelligent diagnosis to reduce the possibility of clinicians' omissions and improve the overall diagnosis quality.**

AmCAD UB[®] Marketing strategy


- ▶ After New Mammogram guideline for Dense Breasts proposed by FDA in Mar. 2019:
 - Hologic acquired Supersonix in Aug.2019.
 - Fujifilm announced to acquire Hitachi (diagnostic imaging BU) in Dec. 2019.

- ▶ Global Breast Ultrasound Market

Value Estimation :

- US\$ 6.4B by 2026; US2.1B in 2018;
CAGR 14.6% (2019~2026)

(from Grand View Research)



- ▶ AmCAD UB (Breast Ultrasound Real-time CADe/x) is going to be integrated into an ultrasound system, therefore, we are in the process of searching for collaboration partnerships (ex. licensing or co-development) with global ultrasound companies, such as GE, Philips, Siemens 、Fujifilm、Cannon、SuperSonic...etc.


Exhibition Plan



Exhibition	Location	Date	Target customers
	Singapore	8/31-9/2	Asia
	Germany-Duesseldorf	11/14-17	Europe 、 Asia
	Arab-Dubai	2023/1/30-2/2	Middle East 、 Asia

Exhibition	Location	Date	Target customers
	US – Chicago	2021/11/28-12/2	America
	Italy – Roman	3/11-16	Europe UO
	Greece– Athens	9/27-30	Europe UO

KOL Professor Li introduces AmCAD UO[®] in his new book



Official Website Exposure



PRODUCTS

NEWS

ABOUT US

INVESTOR

SUSTAINABILITY

CONTACT US

in t f

VIDEO



AmCAD-UT has 510(k) clearance(K203555) and CE mark(NB1639). For further product information e.g. brochure or instruction please use "CONTACT US" below.

甲狀腺大師 - 偵狀甲不瞞 Your best Thyroid Doctor
★最愛 · 5月24日下午6:16 · 0


5月25日為世界甲狀腺日🦋再忙也要關心我們甲狀腺的健康❤️

👉依據國健局2021年12月於癌症登記報告年報統計，2019年初次診斷為甲狀腺惡性腫瘤者共計4,850人，占全部惡性腫瘤發生個案數的4%，發生率的排名於女性為第4位、男性為第12位。

👉超音波為甲狀腺腫瘤最常使用的檢測工具👉醫師透過人工智慧電腦輔助分析甲狀腺結節超音波影像，系統化的對惡性特徵進行計分，作為診斷參考的重要依據。

🦋甲狀腺結節是甲狀腺體中生長出的變異組織，多數為良性，臨床上醫師可由觸診、超音波影像判讀其形態👉細吸抽取(FNA)結節內細胞，在顯微鏡下觀察細胞型態，判斷是否為惡性細胞。

#世界甲狀腺日



成效

觸及人數	心情、留言和分享	Results
總計 485	總計 34	總計 7
這則貼文的觸及人數高於你最近50則 Facebook 貼文和限時動態中的84%。	這則貼文收到的心情數、留言數和分享次數高於你最近50則 Facebook 貼文和限時動態中的97%。	這則貼文獲得的連結點擊次數勝過你50則最新 Facebook 貼文和限時動態中74%的內容。
觸及人數 485	心情數 33 留言數 0 分享次數 1	連結點擊次數 7

Top performance metrics

Stats compared to previous month

Users

1.7K

↑ 57.3%

Sessions

2.1K

↑ 57.7%

Bounce Rate

50.3%

↓ 0.8%

Average Session Duration

00:01:09

↓ 30.2%

User acquisition

Breakdown of visitors acquired by channel



Referral 40.4% Organic Search 29.9% All Other Sessions 29.6%

PRODUCTS INVESTOR CONTACT US

AmCad BioMed Corporation. All Rights Reserved. Web Design- R1D

Internet Media Exposure



Meet AmCad BioMed at Medical Fair Asia
#Ultrasoundai #AI



AmCad BioMed
243 followers
1w • Edited •

A senior woman in her 70s was diagnosed of a [#thyroid](#) nodule 8 years ago. Fine needle aspiration biopsy (FNAB) had been required during her annual follow-up. Her physician recently starts using AmCAD-UT [#ultrasc](#) ...see more



4

1 share

Like

Comment

Be the first to comment on this

Organic impressions: 99 Impressions

Show stats

oMed Corporation

Financial information



Consolidated Balance Sheet



Unit : K TWD

ITEMS	2022.3.31	%	2021.12.31	%
Current Assets	385,473	65	400,544	65
Non-current Assets	211,649	35	215,208	35
Total Assets	597,122	100	615,752	100
Current Liabilities	15,660	2	26,132	4
Non-current Liabilities	9,478	2	10,590	2
Total Liabilities	25,138	4	36,722	6
Capital	532,214	89	532,214	86
Additional Paid-in Capital	95,091	16	94,917	15
Accumulated Deficit	(146,298)	(24)	(138,567)	(22)
Other Equity	(4,537)	(1)	(5,589)	(1)
Parent Equity	476,470	80	482,975	78
Minority Interest	95,514	16	96,055	16
Total Equity	571,984	96	579,030	94
Total Liabilities and Equity	597,122	100	615,752	100

► **Current Ratio: 2461.5% Debt ratio: 4.2%, the financial structure is healthy.**

Consolidated Income Statement

Unit : K TWD

Items	2022Q1		2021Q1		YoY
	AMT	%	AMT	%	%
Sales Revenue	17,229	100	11,725	100	47
Gross Margin	11,639	68	7,264	62	60
Operating Expenses	(22,457)	(131)	(21,663)	(184)	4
Operating Loss	(10,818)	(63)	(14,399)	(122)	(25)
Non-operating Gain	2,546	15	1,070	8	138
Net Loss	(8,272)	(48)	(13,329)	(114)	(38)
Net Loss – Parent	(7,731)	(45)	(11,052)	(94)	(30)
Net Loss – Minority	(541)	(3)	(2,277)	(19)	(24)
EPS (TWD)	(0.15)		(0.21)		

- Because of expanding markets actively , revenues increased by 47% compared with 2021Q1.

THANK YOU.